TGFB1 and neoplasm: A recent report on a phase I/II clinical trial for treatment of chemo-refractory metastatic breast cancer with the TGF-β-neutralizing mAb fresolimumab during radiotherapy did not observe an objective or abscopal response in tumor patients treated with fresolimumab (138, 139).